{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:36:28Z","timestamp":1773246988932,"version":"3.50.1"},"reference-count":92,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1097\/mbc.0b013e32830496a7","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T18:52:31Z","timestamp":1236279151000},"page":"341-348","source":"Crossref","is-referenced-by-count":19,"title":["The use of recombinant factor VIIa in liver diseases"],"prefix":"10.1097","volume":"19","author":[{"given":"Massimo","family":"Franchini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Montagnana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Zaffanello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0955-3886(98)00026-5","article-title":"Clinical use of recombinant FVIIa (rFVIIa)","volume":"19","author":"Hedner","year":"1998","journal-title":"Transfus Sci"},{"issue":"Suppl 1","key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001721-200004001-00005","article-title":"Overall experience with NovoSeven","volume":"11","author":"N\u00e8grier","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00062752-200011000-00015","article-title":"New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate","volume":"7","author":"Kessler","year":"2000","journal-title":"Curr Opin Hematol"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-2001-16890","article-title":"Recombinant activated factor VII (rFVIIa): characterization, manufacturing and clinical development","volume":"27","author":"Jurlander","year":"2001","journal-title":"Semin Thromb Hemost"},{"key":"R5-2-20210203","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1537-2995.2002.00017.x","article-title":"Potential role for rFVIIa in transfusion medicine","volume":"42","author":"Hedner","year":"2002","journal-title":"Transfusion"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1160\/TH05-01-0032","article-title":"Recombinant factor VIIa. An update on its clinical use","volume":"93","author":"Franchini","year":"2005","journal-title":"Thromb Haemost"},{"key":"R7-2-20210203","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.moh.0000135405.29702.3c","article-title":"Recombinant activated factor VIII for nonhemophiliac bleeding patients","volume":"11","author":"Uhlmann","year":"2004","journal-title":"Curr Opin Hematol"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/j.1537-2995.2004.04052.x","article-title":"Transfusion medicine service policies for recombinant factor VIIa administration","volume":"44","author":"Goodnough","year":"2004","journal-title":"Transfusion"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.blre.2003.12.003","article-title":"\u2018Off-license\u2019 use of recombinant activated factor VII","volume":"18","author":"Ghorashian","year":"2004","journal-title":"Blood Rev"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1160\/TH04-03-0163","article-title":"The use of rFVIIa in nonhaemophilia bleeding conditions in paediatrics","volume":"92","author":"Mathew","year":"2004","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000057301","article-title":"The use of recombinant factor VIIa in controlling surgical bleeding in nonhaemophiliac patients","volume":"32","author":"Aldouri","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1182\/blood-2004-06-2223","article-title":"The use of recombinant factor VIIa in the treatment of bleeding disorders","volume":"104","author":"Roberts","year":"2004","journal-title":"Blood"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.curobgyn.2003.12.004","article-title":"Massive postpartum haemorrhage and management of disseminated intravascular coagulation","volume":"14","author":"Macphail","year":"2004","journal-title":"Curr Obstetr Gynaecol"},{"key":"R14-2-20210203","first-page":"431","article-title":"Recombinant activated factor VII for adjunctive hemorrhage control in trauma","volume":"41","author":"Martinowitz","year":"2001","journal-title":"J Trauma"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1471-0528.2006.01156.x","article-title":"The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage","volume":"114","author":"Franchini","year":"2007","journal-title":"BJOG"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1055\/s-2007-1007253","article-title":"The management of abnormalities of hemostasis in acute liver failure","volume":"16","author":"Pereira","year":"1996","journal-title":"Semin Liver Dis"},{"key":"R17-2-20210203","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1055\/s-2002-23205","article-title":"Coagulation disorders in liver disease","volume":"22","author":"Amitrano","year":"2002","journal-title":"Semin Liver Dis"},{"key":"R18-2-20210203","first-page":"466","article-title":"Soluble P selectin levels in chronic liver disease: relationship to disease severity","volume":"54","author":"Vardareli","year":"2007","journal-title":"Hepatogastroenterology"},{"issue":"Suppl D","key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"60D","DOI":"10.1155\/2000\/617428","article-title":"Thrombocytopenia in liver disease","volume":"14","author":"Peck-Radosavljevic","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"R20-2-20210203","doi-asserted-by":"crossref","first-page":"7725","DOI":"10.3748\/wjg.v12.i48.7725","article-title":"New insights into the coagulopathy of liver disease and liver transplantation","volume":"12","author":"Senzolo","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1572-0241.2005.41543.x","article-title":"The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis","volume":"100","author":"Rios","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1042\/cs0990207","article-title":"Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma","volume":"99","author":"Okubo","year":"2000","journal-title":"Clin Sci (Lond)"},{"key":"R23-2-20210203","first-page":"1645","article-title":"Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts","volume":"49","author":"Koruk","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"R24-2-20210203","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1046\/j.1365-2141.2001.02824.x","article-title":"Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis","volume":"113","author":"Adinolfi","year":"2001","journal-title":"Br J Haematol"},{"key":"R25-2-20210203","first-page":"137","article-title":"Effect of alcoholism on hemostasis","volume":"17","author":"Cowan","year":"1980","journal-title":"Semin Hematol"},{"key":"R26-2-20210203","first-page":"964","article-title":"Detection of hepatitis C virus in platelets: evaluating its relationship to viral and host factors","volume":"54","author":"de Almeida","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/jhep.2003.50209","article-title":"A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis","volume":"37","author":"Kajihara","year":"2003","journal-title":"Hepatology"},{"key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.510250607","article-title":"Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis","volume":"25","author":"Feistauer","year":"1997","journal-title":"Hepatology"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1440-1746.2006.04359.x","article-title":"Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura","volume":"22","author":"Kajihara","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0168-8278(98)80290-0","article-title":"Effects of supplementation with unsaturated fatty acids on plasma and membrane lipid composition and platelet function in patients with cirrhosis and defective aggregation","volume":"28","author":"Marra","year":"1998","journal-title":"J Hepatol"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0016-5085(92)90859-W","article-title":"Evidence for a storage pool defect in platelets from cirrhotic patients with defective aggregation","volume":"103","author":"Laffi","year":"1992","journal-title":"Gastroenterology"},{"key":"R32-2-20210203","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0049-3848(78)90018-X","article-title":"A glycoprotein I defect in the platelets of three patients with severe cirrhosis of the liver","volume":"13","author":"Ordinas","year":"1978","journal-title":"Thromb Res"},{"issue":"3 Suppl","key":"R33-2-20210203","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1111\/acer.1998.22.s3_part1.97s","article-title":"Relationship between platelet membrane lipid compositions and platelet aggregability in alcoholic liver disease","volume":"22","author":"Watanabe","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(03)00229-0","article-title":"Kupffer cells are a major source of increased platelet activating factor in the CCl4-induced cirrhotic rat liver","volume":"39","author":"Yang","year":"2003","journal-title":"J Hepatol"},{"key":"R35-2-20210203","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1136\/gut.2003.024893","article-title":"Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis","volume":"53","author":"Yang","year":"2004","journal-title":"Gut"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.3748\/wjg.v13.i27.3677","article-title":"Platelet aggregation is affected by nitrosothiols in patients with chronic hepatitis: in vivo and in vitro studies","volume":"13","author":"Federico","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/gut.27.3.339","article-title":"Haemostatic problems in liver disease","volume":"27","author":"Kelly","year":"1986","journal-title":"Gut"},{"key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1160\/TH03-05-0310","article-title":"Factor VIII expression in liver disease","volume":"91","author":"Hollestelle","year":"2004","journal-title":"Thromb Haemost"},{"key":"R39-2-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.lab.2005.06.003","article-title":"Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis","volume":"146","author":"Fimognari","year":"2005","journal-title":"J Lab Clin Med"},{"key":"R40-2-20210203","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood.V67.1.64.64","article-title":"Biosynthesis and secretion of factor VII, protein C, protein S, and the Protein C inhibitor from a human hepatoma cell line","volume":"67","author":"Fair","year":"1986","journal-title":"Blood"},{"key":"R41-2-20210203","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM198107303050502","article-title":"Acquired vitamin K-dependent carboxylation deficiency in liver disease","volume":"305","author":"Blanchard","year":"1981","journal-title":"N Engl J Med"},{"key":"R42-2-20210203","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0609.1982.tb00588.x","article-title":"Improvement of some blood coagulation factors in cirrhotic patients treated with low dosis heparin","volume":"29","author":"Cordova","year":"1982","journal-title":"Scand J Haematol"},{"key":"R43-2-20210203","first-page":"51","article-title":"Coagulation studies in liver disease","volume":"11","author":"Hallen","year":"1964","journal-title":"Thromb Diath Haemorrh"},{"key":"R44-2-20210203","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood.V67.5.1468.1468","article-title":"Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease","volume":"67","author":"vanDeWater","year":"1986","journal-title":"Blood"},{"key":"R45-2-20210203","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/gut.15.2.83","article-title":"Significance of intravascular coagulation and fibrinolysis in acute hepatic failure","volume":"15","author":"Hilbenbrand","year":"1974","journal-title":"Gut"},{"key":"R46-2-20210203","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2001.03781.x","article-title":"Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit","volume":"96","author":"Hu","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R47-2-20210203","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2141.1976.tb03589.x","article-title":"Abnormal fibrin polymerization in liver disease","volume":"34","author":"Green","year":"1976","journal-title":"Br J Haematol"},{"key":"R48-2-20210203","first-page":"275","article-title":"The extent of diffuse intravascular coagulation and fibrinolysis in patients with liver cirrhosis","volume":"30","author":"van Wersch","year":"1992","journal-title":"Eur J Clin Chem Clin Biochem"},{"key":"R49-2-20210203","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/0016-5085(91)90092-Y","article-title":"A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis","volume":"101","author":"Leebeek","year":"1991","journal-title":"Gastroenterology"},{"issue":"Suppl 5","key":"R50-2-20210203","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1186\/cc3781","article-title":"Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma","volume":"9","author":"Pusateri","year":"2005","journal-title":"Critical Care"},{"key":"R51-2-20210203","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1046\/j.1538-7836.2003.00225.x","article-title":"Mechanism of action of recombinant factor VIIa","volume":"1","author":"Lisman","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R52-2-20210203","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/s-2000-8454","article-title":"The regulation of the factor VII-dependent coagulation pathway: rationale for the effectiveness of recombinant factor VIIa in refractory bleeding disorders","volume":"26","author":"van't Veer","year":"2000","journal-title":"Semin Thromb Hemost"},{"key":"R53-2-20210203","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1046\/j.1538-7836.2003.00181.x","article-title":"How factor VIIa works in hemophilia","volume":"1","author":"Butenas","year":"2003","journal-title":"J Thromb Haemost"},{"key":"R54-2-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/01.ATV.0000042081.57854.A2","article-title":"Influence of factor VIIa and phospholipids on coagulation in \u2018acquired\u2019 hemophilia","volume":"23","author":"Butenas","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R55-2-20210203","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Br J Haematol"},{"key":"R56-2-20210203","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0025-7125(16)30146-8","article-title":"Coagulation defects in liver disease","volume":"78","author":"Mammen","year":"1994","journal-title":"Med Clin North Am"},{"issue":"Suppl 1","key":"R57-2-20210203","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1097\/00001721-200004001-00014","article-title":"Coagulation problems in liver disease","volume":"11","author":"Rapaport","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R58-2-20210203","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/00001721-199811000-00003","article-title":"The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an international normalized ratio above 2.0","volume":"9","author":"Erhardtsen","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R59-2-20210203","first-page":"638a","article-title":"Recombinant factor VIIa (rF-VIIa) successfully and rapidly corrects the excessively high international normalized ratios (INR) and prothrombin times induced by warfarin [abstract]","volume":"96","author":"Deveras","year":"2000","journal-title":"Blood"},{"key":"R60-2-20210203","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7326\/0003-4819-137-11-200212030-00009","article-title":"Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate","volume":"137","author":"Deveras","year":"2002","journal-title":"Ann Int Med"},{"key":"R61-2-20210203","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0016-5085(97)70013-1","article-title":"Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study","volume":"113","author":"Bernstein","year":"1997","journal-title":"Gastroenterology"},{"key":"R62-2-20210203","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1053\/jhep.2002.31771","article-title":"Recombinant factor VIIa improves clot formation but not \ufb01brolytic potential in patients with cirrhosis and during liver transplantation","volume":"35","author":"Lisman","year":"2002","journal-title":"Hepatology"},{"key":"R63-2-20210203","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1537-2995.2006.00824.x","article-title":"Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile","volume":"46","author":"Levy","year":"2006","journal-title":"Transfusion"},{"key":"R64-2-20210203","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.20123","article-title":"Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials","volume":"39","author":"Caldwell","year":"2004","journal-title":"Hepatology"},{"key":"R65-2-20210203","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/003655201750422701","article-title":"Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices","volume":"10","author":"Ejlersen","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"R66-2-20210203","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1542-3565(03)00295-7","article-title":"Recombinant activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices","volume":"2","author":"Romero-Castro","year":"2004","journal-title":"Clinical Gastroenterol Hepatol"},{"key":"R67-2-20210203","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1053\/j.gastro.2004.07.015","article-title":"Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"R68-2-20210203","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1046\/j.0041-1132.2003.00577.x","article-title":"Recombinant FVIIa in the management of uncontrolled hemorrhage","volume":"43","author":"O'Connell","year":"2003","journal-title":"Transfusion"},{"key":"R70-2-20210203","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/jlts.2003.50017","article-title":"Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy","volume":"9","author":"Shami","year":"2003","journal-title":"Liver Transpl"},{"key":"R71-2-20210203","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00005176-200309000-00013","article-title":"Recombinant factor VIIa improves coagulopathy caused by liver failure","volume":"37","author":"Brown","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R72-2-20210203","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00000542-200502000-00006","article-title":"Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial","volume":"102","author":"Lodge","year":"2005","journal-title":"Anestesiology"},{"key":"R73-2-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.amjsurg.2005.10.019","article-title":"Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"191","author":"Shao","year":"2006","journal-title":"Am J Surg"},{"key":"R75-2-20210203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1055\/s-0037-1613000","article-title":"Successful use of recombinant activated factor VII (NovoSeven) in controlling severe intra-abdominal bleeding after liver needle biopsy","volume":"87","author":"Hoffman","year":"2002","journal-title":"Thromb Haemost"},{"key":"R76-2-20210203","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0168-8278(99)80357-2","article-title":"Correction of both prothrombin time and primary hemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis","volume":"31","author":"Pasi","year":"1999","journal-title":"J Hepatol"},{"key":"R77-2-20210203","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1055\/s-0037-1616549","article-title":"Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP)","volume":"86","author":"Kositchaiwat","year":"2001","journal-title":"Thromb Haemost"},{"key":"R78-2-20210203","first-page":"280","article-title":"Small dose of recombinant factor VIIa (rFVIIa) to perform percutaneous liver biopsies in cirrhotic patients","volume":"94","author":"Carvalho","year":"2002","journal-title":"Rev Esp Enferm Dig"},{"key":"R79-2-20210203","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/gast.2002.34164","article-title":"Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy","volume":"123","author":"Jeffers","year":"2002","journal-title":"Gastroenterology"},{"key":"R80-2-20210203","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/lt.20447","article-title":"The role of recombinant factor VIIa in liver transplantation","volume":"11","author":"Porte","year":"2005","journal-title":"Liver Transpl"},{"key":"R81-2-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00004311-200604430-00009","article-title":"The place of recombinant activated factor VII in liver transplantation","volume":"44","author":"Gibbs","year":"2006","journal-title":"Int Anasthesiol Clin"},{"key":"R82-2-20210203","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0041-1345(98)01669-8","article-title":"Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII","volume":"31","author":"Kalicinski","year":"1999","journal-title":"Transplant Proc"},{"key":"R83-2-20210203","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/00007890-200102150-00011","article-title":"Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study","volume":"71","author":"Hendriks","year":"2001","journal-title":"Transplantation"},{"key":"R84-2-20210203","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/S0041-1345(03)00759-0","article-title":"Rapid correction of prothrombin time after low-dose recombinant factor VIIa in patients undergoing orthotopic liver transplantation","volume":"35","author":"Surudo","year":"2003","journal-title":"Transplant Proc"},{"key":"R85-2-20210203","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00001721-200302000-00008","article-title":"Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis","volume":"14","author":"Meijer","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R86-2-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-3148.2006.00653.x","article-title":"Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores","volume":"16","author":"Niemann","year":"2006","journal-title":"Transf Med"},{"key":"R87-2-20210203","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-3046.2005.00309.x","article-title":"Single pretransplant bolus of recombinant activated factor VII ameliorates influence of risk factors for blood loss during orthotopic liver transplantation","volume":"9","author":"Kalicinski","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R88-2-20210203","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/lt.20458","article-title":"Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease","volume":"11","author":"Planinsic","year":"2005","journal-title":"Liver Transplant"},{"key":"R89-2-20210203","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/lt.20470","article-title":"Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation","volume":"11","author":"Lodge","year":"2005","journal-title":"Liver Transpl"},{"key":"R90-2-20210203","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.transproceed.2007.05.062","article-title":"Activated recombinant factor VII in orthotopic liver transplantation","volume":"39","author":"Pugliese","year":"2007","journal-title":"Transplant Proc"},{"key":"R91-2-20210203","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10620-005-9023-y","article-title":"A cerebrovascular event after single-dose administration of recombinant factor VIIa in a patient with esophageal variceal bleeding","volume":"51","author":"Akyildiz","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R92-2-20210203","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/BF03018576","article-title":"FVIIa corrects the coagulopathy of fulminant hepatic failure but may be associated with thrombosis: a report of four cases","volume":"52","author":"Pavese","year":"2005","journal-title":"Can J Anaesth"},{"key":"R93-2-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1423-0410.2006.00888.x","article-title":"Recombinant-activated coagulation factor VIIa (NovoSeven): current development","volume":"92","author":"Weiskopf","year":"2007","journal-title":"Vox Sang"},{"key":"R94-2-20210203","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/cc5026","article-title":"Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding\u2013 a European perspective","volume":"10","author":"Vincent","year":"2006","journal-title":"Crit Care"}],"container-title":["Blood Coagulation & Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00001721-200807000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:09:39Z","timestamp":1618034979000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001721-200807000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0b013e32830496a7","relation":{},"ISSN":["0957-5235"],"issn-type":[{"value":"0957-5235","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}